United Therapeutics Corp.'s experimental drug-device combination to treat pulmonary arterial hypertension has been accepted for review by the U.S. Food and Drug Administration.
The regulatory body is expected to give its decision on the Silver Spring, Md.-based company's application by April 27, 2020.
Pulmonary arterial hypertension is a rare type of high blood pressure that affects arteries in the lungs and the right side of the heart. It is characterized by dizziness and chest pressure.
Trevyent is being developed as a combination of treprostinil and the PatchPump technology, to be administered via injections.
Both Trevyent and the PatchPump technology are propriety products of SteadyMed Ltd., a subsidiary of United Therapeutics.
